Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women

Iris Garrido-Cano; Marta Tapia; Juan Carbonell; Carlos Peña; Sandra Torres-Ruiz; Anna Ágreda-Roca; Ana Lameirinhas; Cristina Tebar; Octavio Burgués; Cristina Hernando; Ana Lluch; Fara Brasó-Maristany; Aleix Prat; Begoña Bermejo; María Teresa Martínez; Juan Miguel Cejalvo

doi:10.1002/cac2.70019

Cancer Communications ›› 2025, Vol. 45 ›› Issue (7) : 789 -793. DOI: 10.1002/cac2.70019

LETTER TO THE JOURNAL

Deciphering the transcriptomic landscape of early HR⁺/HER2⁻ breast cancer in very young women

Author information +

¹. Biomedical Research Institute INCLIVA, Valencia, Spain

². Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain

³. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Valencia, Spain

⁴. Medical Oncology Department, Hospital Clínico Universitario of Valencia, Valencia, Spain

⁵. Pathology Department, Hospital Clínico Universitario of Valencia, Valencia, Spain

⁶. Department of Medicine, Universitat de València, Valencia, Spain

⁷. Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain

⁸. Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain

⁹. Institute of Cancer and Blood Disorders, Hospital Clinic of Barcelona, Barcelona, Spain

martinez_mtemar@gva.es

jmcejalvo@incliva.es

Show less

History +

PDF

Cite this article

Download citation ▾

Iris Garrido-Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres-Ruiz, Anna Ágreda-Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó-Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo. Deciphering the transcriptomic landscape of early HR⁺/HER2⁻ breast cancer in very young women. Cancer Communications, 2025, 45(7): 789-793 DOI:10.1002/cac2.70019

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Cai S, Zuo W, Lu X, Gou Z, Zhou Y, Liu P, et al. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis. Front Oncol. 2020; 10: 1729.

[2]	Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014; 16: 427.

[3]	Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379: 111–21.

[4]	Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021; 385: 2336–47.

[5]	Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Clin Cancer Res. 2017; 23: 3035–44.

[6]	Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5): 541–50.

[7]	Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol. 2019; 10: 440886.

[8]	Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577: 549–55.

[9]	Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6: 676–84.

[10]

Cardoso F, McArthur HL, Schmid P, Cortés J, Harbeck N, Telli ML, et al. KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Ann Oncol. 2023; 34: S1260–1.